The recent suspension of an Air India pilot following a reported positive test for cannabis has reignited a complex, lingering debate at the intersection of aviation safety and biological science. In a high-stakes industry where the margin for error is non-existent, the immediate reaction to such a headline is understandably one of alarm. Yet, beneath the surface of zero-tolerance policies lies a more nuanced reality about what these diagnostic tools are actually capable of measuring.
Unlike alcohol, which metabolizes quickly and correlates directly with active impairment, cannabis leaves a lingering chemical footprint. Metabolites can remain locked in the body’s fat tissues for days, weeks, or even months after consumption, long after any psychoactive effects have subsided. Consequently, a positive screen tells investigators that a substance was ingested at some point in the recent past, but it remains frustratingly silent on the crucial question of active impairment during flight.
This biological ambiguity presents a modern regulatory dilemma. As global attitudes toward cannabis soften and legalization spreads, safety-critical industries must grapple with the limitations of their own testing regimes. To ensure true skyward integrity, the aviation sector may eventually need to transition from historical detection to real-time cognitive assessment—measuring a pilot's actual readiness to fly rather than chasing the chemical ghosts of weeks gone by.